Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 517-523

  Ceresa, Cecilia ^a   Avan, Abolfazl ^b,c   Giovannetti, Elisa ^b   Geldof, Albert A ^b   Avan, Amir ^b,c   Cavaletti, Guido ^a   Peters, Godefridus J ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amifostine neuroprotection; Cyclin B2; Neurotoxicity; Oxaliplatin; PC12 model

Indexed keywords

AMIFOSTINE; BORTEZOMIB; CYCLIN B2; EPOTHILONE B; OXALIPLATIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, RAT; BORONIC ACID DERIVATIVE; CCNB2 PROTEIN, RAT; EPOTHILONE DERIVATIVE; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PLATINUM COMPLEX; PYRAZINE DERIVATIVE; RADIOPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELL COUNTING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; IN VITRO STUDY; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEURITE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PHEOCHROMOCYTOMA CELL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADRENAL TUMOR; AMIFOSTINE NEUROPROTECTION; ANIMAL; ARTICLE; CELL DIFFERENTIATION; CYCLIN-B2; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PC12 MODEL; PHEOCHROMOCYTOMA; REAL TIME POLYMERASE CHAIN REACTION; TOXICITY AND INTOXICATION; TUMOR CELL CULTURE;

AMIFOSTINE NEUROPROTECTION; CYCLIN-B2; NEUROTOXICITY; OXALIPLATIN; PC12 MODEL;

ADRENAL GLAND NEOPLASMS; AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL DIFFERENTIATION; CYCLIN B2; EPOTHILONES; MICROTUBULE-ASSOCIATED PROTEINS; NEURITES; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PHEOCHROMOCYTOMA; PYRAZINES; RADIATION-PROTECTIVE AGENTS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84897021053     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Cavaletti G, Alberti P, Frigeni B, Piatti M and Susani E: Chemotherapy-induced neuropathy. Curr Treat Options Neurol 13(2): 180-190, 2011.
2. Argyriou AA, Bruna J, Marmiroli P and Cavaletti G: Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 82(1): 51-77, 2012.
3. Stillman M and Cata JP: Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 10(4): 279-287, 2006.
4. Armstrong T, Almadrones L and Gilbert MR: Chemotherapyinduced peripheral neuropathy. Oncol Nurs Forum 32(2): 305-311, 2005.
5. Cavaletti G and Marmiroli P: Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf 3(6): 535-546, 2004.
6. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M and De Coster R: Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204(1): 317-325, 2007.
7. Cersosimo RJ: Oxaliplatin-associated neuropathy: A review. Ann Pharmacother 39(1): 128-135, 2005.
8. Lee JJ and Swain SM: Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10): 1633-1642, 2006.
9. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4(5): 349-360, 2004.
10. Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL and Kessler BM: Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 65(17): 7896-7901, 2005.
11. Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H and Giaccone G: A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 13(12): 3642-3651, 2007.
12. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J and Spriggs DR: Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23(25): 5943-5949, 2005.
13. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM and Dees EC: Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105(8): 3058-3065, 2005.
14. Goodin S, Kane MP and Rubin EH: Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22(10): 2015-2025, 2004.
15. Altmann KH, Wartmann M and O'Reilly T: Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470(3): M79-M91, 2000.
16. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC and Fojo T: A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97(6): 2904-2909, 2000.
17. Goodin S: Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer. Am J Health Syst Pharm 65(21): 2017-2026, 2008.
18. Lee JJ and Swain SM: Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 32(6 Suppl 7): S22-S26, 2005.
19. Chiorazzi A, Nicolini G, Canta A, Oggioni N, Rigolio R, Cossa G, Lombardi R, Roglio I, Cervellini I, Lauria G, Melcangi RC, Bianchi R, Crippa D and Cavaletti G: Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies. Neurobiol Dis 35(2): 270-277, 2009.
20. Authier N, Gillet JP, Fialip J, Eschalier A and Coudore F: An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 182(1): 12-20, 2003.
21. McDonald ES and Windebank AJ: Cisplatin-induced apoptosis of DRG neurons involves BAX redistribution and cytochrome c release but not FAS receptor signaling. Neurobiol Dis 9(2): 220-233, 2002.
22. Capizzi RL: Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): Clinical experiences. Semin Oncol 21(5 Suppl 11): 8-15, 1994.
23. Ng TY, Ngan HY, Cheng DK and Wong LC: The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines. Gynecol Oncol 75(2): 194-197, 1999.
24. Peters GJ and van der Vijgh WJ: Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cancer 31A(Suppl 1): S1-S7, 1995.
25. Mollman JE, Glover DJ, Hogan WM and Furman RE: Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61(11): 2192-2195, 1988.
26. Treskes M and van der Vijgh WJ: WR2721 as a modulator of cisplatin- and carboplatin-induced side-effects in comparison with other chemoprotective agents: A molecular approach. Cancer Chemother Pharmacol 33(2): 93-106, 1993.
27. Verstappen CC, Geldof AA, Postma TJ and Heimans JJ: In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065. J Neurooncol 44(1): 1-5, 1999.
28. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, and Cavaletti G:.Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14(4): 343-350, 2010.
29. Geldof AA: Nerve-growth-factor-dependent neurite outgrowth assay; A research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol 121(11): 657-660, 1995.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13): 1107-1112, 1990.
31. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B and Pinedo HM: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27(7): 897-900, 1991.
32. Geldof AA, Mastbergen SC, Henrar RE and Faircloth GT: Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol 44(4): 312-318, 1999.
33. Nicolini G, Miloso M, Zoia C, Di Silvestro A, Cavaletti G and Tredici G: Retinoic acid differentiated SH-SY5Y human neuroblastoma cells: An in vitro model to assess drug neurotoxicity. Anticancer Res 18(4A): 2477-2481, 1998.
34. Casafont I, Berciano MT and Lafarga M: Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in SAM68 and PABPN1 in sensory ganglia neurons. Neurotox Res 17(2): 167-178, 2010.
35. Bruna J, Udina E, Ale A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L and Navarro X: Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223(2): 599-608, 2010.
36. Chiorazzi A, Hochel J, Stockigt D, Canta A, Carozzi VA, Meregalli C, Avezza F, Crippa L, Sala B, Ceresa C, Oggioni N and Cavaletti G: Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model. Neurotox Res 22(2): 91-101, 2012.
37. Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, and Fojo T: A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 16(5): 1634-1641, 2010.
38. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T and Swain SM: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23(12): 2726-2734, 2005.
39. Tan MH, Chay WY, Ng JH, Teh BT and Chew L: Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: A case report. J Med Case Rep 4: 36, 2010.
40. Lu P, Fan QX, Wang LX, Wang X, Zong H and Wang RL: Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors. Ai Zheng 27(10): 1117-1120, 2008
41. Oe T, Nagashima T, Muramoto M, Yamazaki T, Morikawa N, Okitsu O, Nishimura S, Aoki T, Katayama Y and Kita Y: Cyclin B2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology 50(8): 1041-1047, 2006.
42. Erhardt JA and Pittman RN: Ectopic p21(WAF1) expression induces differentiation-specific cell cycle changes in PC12 cells characteristic of nerve growth factor treatment. J Biol Chem 273(36): 23517-23523, 1998.
43. Dobashi Y, Shoji M, Kitagawa M, Noguchi T and Kameya T: Simultaneous suppression of Cdc2 and Cdk2 activities induces neuronal differentiation of PC12 cells. J Biol Chem 275(17): 12572-12580, 2000.
44. Chiu SJ, Lee YJ, Hsu TS and Chen WS: Oxaliplatin-induced γ- H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells. Chem Biol Interact 182(2-3): 173-182, 2009.